The FDA is considering giving outside experts the ability to access and analyze "masked" and "de-identified" trial data derived from device and drug approval applications. The agency is seeking comments on the proposal, which it says could offer new opportunities for innovation in drugs, biologics and devices.

Full Story:

Related Summaries